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640Objectives: To compare the decrease in left ventricular mass index (LVMI) by magnetic resonance imaging
(MRI) versus transthoracic echocardiography (TTE) after aortic valve replacement (AVR) for severe aortic ste-
nosis with Epic and Epic Supra stented porcine bioprostheses (St Jude Medical, Inc, St Paul, Minn).
Methods: This prospective multicenter study enrolled 149 patients who underwent AVR between January 2006
and February 2008. TTE and cardiac MRI measurements of LVMI were made at baseline and at 6 months of
follow-up and were compared. Changes in mean pressure gradients were examined using TTE.
Results: TTE measurements of LVMI were 48% to 63% higher than the MRI measurements. A decrease in
LVMI from 137  32 to 95  16 g/m2 with the Epic and from 139  29 to 104  28 g/m2 with the Epic Supra
valves (P<.0001 for both comparisons) was measured by TTE. Cardiac MRI revealed decreases in LVMI from
84  20 to 64  12 g/m2 and from 86  27 to 64  17 g/m2 with the Epic and Epic Supra valves, respectively
(P<.0001 for both comparisons). TTE revealed a significant regression of mean pressure gradients from 51.6
15.3 to 15.5  5.2 mm Hg with the Epic and from 46.7  19.4 to 17.9  12.8 mm Hg with the Epic supra
(P<.0001 for both comparisons).
Conclusions: A significant decrease in LVMI was measured after AVR with all sizes of both bioprosthetic
models. Because of the overestimation of the decrease in LVMI by the Devereux formula, as well as the higher
accuracy and reproducibility of cardiac MRI measurements, the latter should be preferred to TTE. An ultimate
validation of this thesis could only be done comparing each of these modalities with pathologic examination.
(J Thorac Cardiovasc Surg 2012;144:640-5)Supplemental material is available online.
Aortic valve replacement (AVR) remains the main treat-
ment of severe aortic stenosis (AS).1 Several studies have
confirmed the benefit it confers on long-term survival,
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The Journal of Thoracic and Cardiovascular Surgattributable to a decrease in left ventricular (LV) pressure
overload, allowing the decrease in LV mass and
regression of hypertrophy.
LV mass is an independent predictor of cardiovascular
morbidity and mortality.4 It is crucial in patients who
have severe, symptomatic AS to lower the LV afterload
and normalize the LV mass, a process that takes place
mainly within the first 3 postoperative months. However,
significant LV hypertrophy persists in a subset of patients.5
Systemic hypertension and a small prosthetic valve are 2
causes of persistent LV hypertrophy after surgical AVR,6,7
underscoring the importance of an optimal postoperative
treatment plan to (1) achieve the greatest amount of
decrease in LV mass and (2) most reliably ascertain its
changes.
Most studies of LV mass and its decrease after AVR
have used transthoracic echocardiography (TTE), a method
that is readily available and that uses geometric assump-
tions that have been validated in normal hearts.8 However,
in the presence of asymmetric LV hypertrophy, the LV
mass may be overestimated.9,10 Moreover TTE is (1)
dependent on the acoustic window and (2) subject to
interobserver and intraobserver variability.11 In contrast,
cardiovascular magnetic resonance imaging (MRI) enables
the acquisition of high-resolution images in any plane,ery c September 2012
Abbreviations and Acronyms
AS ¼ aortic stenosis
AVR ¼ aortic valve replacement
CABG ¼ coronary artery bypass graft
LV ¼ left ventricular
LVMI ¼ left ventricular mass index
MRI ¼ magnetic resonance imaging
REST ¼ Left Ventricular Regression European
Study
TTE ¼ transthoracic echocardiography
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Dunlimited by an acoustic window and without exposure to
radiation, producing measurements that are accurate and
highly reproducible.
The objective of this prospectivemulticenter study was to
compare the decrease in LV mass measured by MRI versus
that measured by TTE, 6 months after AVR, using the Epic
and Epic Supra bioprostheses (St JudeMedical, Inc, St Paul,
Minn).STUDY POPULATION AND METHODS
The Left Ventricular Regression European STudy (REST) was con-
ducted at 8 European medical centers. The data were collected by study co-
ordinators appointed at each participating center, analyzed by an
independent core laboratory, and monitored by St Jude Medical, the study
sponsor. The protocol was approved by the research ethics committee of
each participating center, and all patients granted their written informed
consent to participate in the study.
Sample Size Calculation
The sample size calculation was based on the main end point of the
study, that is, change in LV mass index (LVMI) between baseline and 6
months. Baseline is defined as before intervention. According to Bech-
Hanssen and associates,12 it was assumed that the mean change of LVMI
using echocardiography for all biological valves will be 18.35% with an
estimated standard deviation of 17.35%.
For sample size calculations, it was assumed that the mean change of
LVMI using MRI will be 25%, with the same standard deviation as the
one for mean change of LVMI using echocardiography, that is, 17.35%.
Moreover, several values were assumed for the correlation between the
change in LVMI using MRI and using echocardiography. Assuming
a veryweak association of 0.2, a 2-sided paired t test will detect a significant
difference (5% significance level and power at least 90%) in change of
LVMI between echocardiography and MRI when 117 analyzable patients
are recruited. If the correlation is 0.4, then 88 patients should be recruited.
If the correlation is higher, the sample size required will decrease.
Study Eligibility
Patients of legal age in their host country, who underwent a first AVR for
severe AS or for mixed aortic valve disease with predominant AS, were
considered for study enrollment. In February 2007, an amendment to the
protocol was introduced, which allowed the enrollment of patients under-
going AVR with concomitant coronary artery bypass graft (CABG) sur-
gery. Patients were excluded from the study if they were pregnant or
nursing, on hemodialysis, or had unstable angina, active endocarditis, acute
aortic dissection, NewYork Heart Association heart failure functional classThe Journal of Thoracic and CaIV, or prominent LV wall motion abnormality, chronic or persistent atrial
fibrillation, or claustrophobia. Further exclusion criteria were the presence
of a permanent pacemaker or implantable cardioverter defibrillator, aneu-
rysmal clip, carotid artery stent, neurostimulator, cochlear or other ear im-
plant, temporary or permanently implanted drug infusion device, bone
growth or fusion stimulator, and ocular foreign body.
Study Design
This was an international, multicenter, prospective, observational study.
Demographic and clinical characteristics, health history, concomitant med-
ications, and baseline laboratory values were recorded in all patients. The
patients were scheduled to return for ambulatory follow-up visits at
6-month (time frame from 180 to 270 days) intervals after their discharge
from the hospital. TTE and MRI were performed at baseline and at 6
months of follow-up.
Implanted Valve Models
Epic and Epic Supra are stented porcine bioprostheses. The choice of
Epic versus Epic Supra valve implanted in this study was left to the sur-
geon’s discretion.
TTE
All TTEs were performed by expert sonographers at site, trained on
study echocardiography protocol, and analyzed at an independent core lab-
oratory (U.Z. Gasthuisberg, Department of Cardiology, Leuven, Belgium)
by observers highly trained in qualitative, quantitative, and Doppler ultra-
sonography. Two-dimensional, M-mode, and Doppler images were ob-
tained in standard apical, subcostal, suprasternal, and parasternal views.
Measurements were performed according to the guidelines issued by the
American Society of Echocardiography.13 LV mass was calculated using
the Devereux formula.
Cardiac MRI
MRIwas performed during continuous electrocardiographicmonitoring
using 5 different scans. The new, balanced, steady-state free precession
cine MRI sequences were used for the measurements of LV volumes,
mass, and function in scans 3, 4, and 5. For the cine MRIs in the short
axis, an 8-mm thick continuous slice was used with a repetition time of
35ms or less. LVend-diastolic volume, LVend-systolic volume, stroke vol-
ume, LV mass, and their associated indices, and LVejection fraction were
calculated by an independent MRI core laboratory (U.Z. Gasthuisberg, De-
partment of Radiology, Leuven, Belgium) using a custom-made software
(CardioViewer; Catholic University Leuven, Leuven, Belgium).14 The en-
docardial trabeculations and papillary muscles were included in the LV
wall measurements.
Statistical Analysis
Continuous variables are presented as means  standard deviation and
were compared with the Student t test or Wilcoxon nonparametric test, as
appropriate. Categorical data are presented as counts and percentages. The
relationship between measurements of LV mass and LVMI by MRI versus
echocardiography was examined using the Spearman rank correlation co-
efficients and associated P values. All statistical analyses were performed
with SAS software, version 9.1 (SAS Institute Inc, Cary, NC).RESULTS
Study Population
A total of 149 patients were enrolled in the REST study
between January 2006 and June 2008. Their mean age was
73.3  8.6 years and 57% were women. The main baseline
characteristics of the study population are shown in Table 1.rdiovascular Surgery c Volume 144, Number 3 641
TABLE 1. Baseline characteristics of the 149 study patients
Age, y 73.3  8.6
Women 85 (57)
Height, cm 164.2  9.7
Body
Weight, kg 75.1  14.1
Mass index, kg/m2 27.9  4.9
Surface area, m2 1.8  0.2
Log EuroSCORE 6.6  4.0
New York Heart Association functional class
I 21 (14%)
II 86 (58%)
III 42 (28%)
Values are means  standard deviation or numbers (%) of observations.
TABLE 2. Intraoperative observations
Valve sizes, mm
Epic Supra
19 10 (7)
21 38 (26)
23 24 (16)
Epic
21 7 (5)
23 39 (26)
25 22 (15)
27 9 (6)
Aortic valve lesions
Stenosis 54 (36)
Mixed stenosis and insufficiency 95 (64)
Calcifications
Annular 97 (65)
Leaflet 134 (90)
Leaflet thickening 149 (100)
Commissural fusion 47 (32)
Concomitant procedures
None 109 (73)
Coronary artery bypass graft 26 (17)
Aortoplasty 11 (7)
Replacement of ascending aorta 2 (1)
Other 9 (6)
Duration, min
Cardiopulmonary bypass 96  34
Crossclamp 70  24
Values are means  standard deviation or numbers (%) of observations.
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Fifty-four (36%) patients had pure AS and 95 (64%) had
aortic insufficiency and predominant stenosis (Table 2). The
peak and mean pressure gradients at baseline were 81  28
and 49  18 mm Hg, respectively, and mean effective
orifice area was 0.80  0.34 cm2.
Of the 149 patients, 109 underwent isolated AVR, 26
underwent concomitant CABG, and 22 underwent other ad-
ditional procedures (Table 2). The sizes of the 77 Epic and
72 Epic Supra bioprostheses implanted in this study are de-
tailed in Table 2. The mean duration of cardiopulmonary
bypass was 96  34 minutes and mean duration of cross-
clamping was 70  24 minutes. Further intraoperative ob-
servations and measurements are shown in Table 2.Postoperative Outcomes and Analyzable Data
The short- and long-term clinical outcomes and ultimate
data availability are shown in Table E1.
Short-term outcome. The overall duration of ventilator
support ranged from 5 to 53 hours, the mean stay in the in-
tensive care unit ranged from 6 to 163 hours, and the dura-
tion of hospitalization ranged from 5 to 76 days. At 30 days
after the operation, 3 (2.0%) of the 149 patients had died,
including 1 patient on postoperative day 9 of ventricular
fibrillation, 1 patient on day 11 of acute cardiac decompen-
sation and pulmonary edema, and 1 patient on day 12 of un-
witnessed sudden death. Major intrathoracic hemorrhages
requiring reoperations occurred in 4 (2.7%) patients and
hemorrhages treated with transfusions of blood products
in 3 (2.0%) patients. Atrial fibrillation developed in 12
(8.1%) and complete heart block requiring permanent pac-
ing in 8 (5.3%) patients. Other complications included
a major hemorrhage on postoperative day 6 from a duodenal
ulcer in 1 (0.7%) patient and large pericardial effusions in 3
(2.0%) patients, treated with diuretics, open drainage, and
pericardiocentesis in 1 patient each.
Long-term outcome. Over a mean follow-up of 7.1
months and cumulative follow-up of 1052 months, 2 addi-
tional patients died, of renal failure and liver cirrhosis,642 The Journal of Thoracic and Cardiovascular Surgrespectively, for an overall mortality of 3.4%. Valve throm-
bosis treated with cleaning of the valve leaflets on postoper-
ative day 102 and embolic stroke on postoperative day 116
occurred in 1 patient each. Furthermore, 7 patients with-
drew from the study, 1 was lost to follow-up, 2 had pace-
makers implanted, and 13 patients had incomplete or
untimely collections of data (Table E1). At the end of
follow-up, complete and paired echocardiographic and
MRI data were available in 109 patients (complete MRI
data in 111 patients and complete echocardiographic data
in 118 patients).Echocardiographic Observations at Baseline Versus
6 Months of Follow-up
The changes in echocardiographic measurements associ-
ated with each valve model and each valve size between
baseline and 6 months of follow-up are summarized in
Tables 3 and 4. LV mass and LVMI both decreased
significantly with each model and each valve size
(Table 3 and Table 4). Likewise, LVend-diastolic diameter,
LVend-diastolic posterior wall and septal thickness, and LV
end-diastolic volume decreased significantly. LV end-
systolic volume, however, decreased significantly in the
Epic group only. Mean LV ejection fraction was normal at
baseline in both valve model groups and increasedery c September 2012
TABLE 3. Echocardiographic and MRI observations at baseline versus 6 months of follow-up
Measurements Valve model
Echocardiography MRI
Baseline 6 mo P Baseline 6 mo P
Left ventricular
Mass, g Epic 258  65 178  37 <.0001 160  41 120  28 <.0001
Epic supra 243  51 180  47 <.0001 151  47 110  30 <.0001
Mass index, g/m2 Epic 137  32 95  16 <.0001 84  20 64  12 <.0001
Epic supra 139  29 104  28 <.0001 86  27 64  17 <.0001
End-distolic, mm
Diameter Epic 45.9  5.2 43.0  4.0 <.0001
Epic supra 44.3  5.5 40.7  5.7 <.0001
Thickness
Posterior wall Epic 12.9  1.3 10.9  1.0 <.0001
Epic supra 12.9  1.4 11.4  1.3 <.0001
Septum Epic 14.8  2.0 12.3  1.6 <.0001
Epic supra 14.8  1.8 13.1  2.1 <.0001
Volume, cm3 (TTE)
Volume, mL (MRI)
End-ddiastolic Epic 110  29 98  17 <.0001 131  36 117  23 .01
Epic supra 104  36 92  23 .026 125  47 110  28 .002
End-systolic Epic 35  16 31  10 .0032 45  29 44  31 <.0001
Epic supra 32  18 28  10. .066 30  13 29  20 <.0001
Ejection fraction,% Epic 68.8  6.3 68.7  6.8 .19 67.7  12.5 74.4  8.1 <.0001
Epic supra 68.2  8.8 70.6  5.1 .002 68.9  14.6 74.9  10.4 <.0001
Transvalvular pressure gradient, mm Hg
Peak Epic 85.2  25.2 28.5  10.7 <.0001
Epic supra 77.3  30.0 31.9  18.3 <.0001
Mean Epic 51.6  15.3 15.5  5.2 <.0001
Epic supra 46.7  19.4 17.9  12.8 <.0001
Effective orifice area, cm3 Epic 0.8  0.3 1.4  0.3 <.0001
Epic supra 0.8  0.4 1.3  0.3 <.0001
Effective orifice area index, cm3/m2 Epic 0.4  0.1 0.8  0.2 <.0001
Epic supra 0.5  0.2 0.7  0.2 <.0001
Cardiac output, L/min Epic 5.3  1.6 4.5  1.2 <.0001 5.9  1.4 5.6  1.3 .62
Epic supra 5.3  1.2 4.5  1.2 .0039 5.3  1.4 5.3  1.2 .67
Cardiac index, L $ min1 $ m2 Epic 2.8  0.8 2.4  0.6 <.0001 3.2  0.8 3.0  0.7 .72
Epic supra 3.0  0.7 2.6  0.7 .0079 3.0  0.8 3.1  0.6 .76
Values are means  standard deviation. Paired transthoracic echocardiographic (TTE) observations were available in 58 recipients of Epic and 60 recipients of Epic Supra bio-
prostheses. Paired magnetic resonance imaging (MRI) observations were available in 53 recipients of Epic and 58 recipients of Epic Supra bioprostheses.
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(P ¼ .002) in the Epic Supra group only (Table 3).
Cardiac MRI Observations at Baseline Versus 6
Months of Follow-up
At 6 months of follow-up, LV mass and LVMI
(P<.0001), LV end-diastolic volume (P<.0001) and LV
end-systolic volume (P¼ .003) had decreased and LVejec-
tion fraction had increased (P< .0001) significantly with
both valve models and each valve size (Tables 3 and 4).
Cardiac output and cardiac index remained unchanged
with both valve models (Table 3).
Decrease in LV Mass on TTE Versus Cardiac MRI
Despite moderate correlations observed at baseline
(r ¼ 0.54) and at 6 months of follow-up (r ¼ 0.62)The Journal of Thoracic and Cabetween the LVMI measured by TTE versus MRI, the
measurements made by TTE were systematically and sig-
nificantly higher (P<.0001) than the measurements made
by MRI (Table 3).
Effects of Concomitant CABG Surgery
In February 2007, a protocol amendment was introduced
allowing the enrolment in REST of patients undergoing
AVR and concomitant CABG who had severe AS and no
major LVwall motion abnormality. A comparison of the de-
mographic characteristics of 26 patients who underwent
concomitant CABG, versus 123 patients who did not, re-
vealed no significant difference (Table E2). Likewise, no
differences were observed between the 2 groups in (1)
TTE-measured baseline LV ejection fraction, (2) TTE-
measured LV mass at 6 months and at follow-up, and (3)rdiovascular Surgery c Volume 144, Number 3 643
TABLE 4. Regression of LV mass and LVMI by valve type and size
Measurements
Valve type and size in mm
Epic 21 Epic 23 Epic 25 Epic 27 Epic Supra 19 Epic Supra 21 Epic Supra 23
LV mass, g
MRI
Baseline 128  19 155  43 170  35 178  45 163  72 148  41 150  46
6 mo 101  0.4 114  28 125  29 131  25 111  46 111  26 111  28
TTE
Baseline 207  48 253  68 264  63 290  55 240  68 242  50 246  46
6 mo 159  15 168  38 182  34 207  32 183  65 180  38 179  53
LVMI, g/m2
MRI
Basline 72  10 83  21 89  18 92  24 97  46 86  25 82  20
6 mo 56  3 63  13 65  12 67  14 65  28 64  16 62  11
TTE
Baseline 121  31 136  31 139  34 149  28 141  41 140  31 137  20
6 mo 88  13 94  15 94  17 106  18 107  37 105  26 100  29
Values are means standard deviation. For the different valve types and the valve sizes there is a significant regression of left ventricular (LV)mass and left ventricular mass index
(LVMI) comparing baseline to 6 months’ follow-up (P ¼ .02 for 19-mm and 27-mm valves, P<.0001 for all other valve sizes). MRI,Magnetic resonance imaging; TTE, trans-
thoracic echocardiography.
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line and 6 months of follow-up.
DISCUSSION
AS causes LV pressure overload and a marked hypertro-
phic response of the myocardium as an adaptive response to
the increased wall stress.6 This, in turn, causes an increase
in LV mass, which is strongly correlated with an increased
cardiac mortality and morbidity.4 Therefore, it is crucial in
patients with severe, symptomatic AS to decrease the LV
mass to normal levels. It has been previously observed
that LVmass may not return to normal after AVR for AS be-
cause of other factors, such as poorly controlled hyperten-
sion or patient–prosthesis mismatch.6,7 In this study, an
approximately 25% regression of LV mass and LVMI
was observed with all sizes of both bioprosthetic models
at 6 months after AVR, an observation concordant with
the 15% to 38% decrease reported by previous
studies.15-17 The impact of the various valve models and
sizes implanted on the regression of LV mass remains
controversial. Some investigators found a lesser decrease
in LV mass with small than large valves,12,18 whereas
others observed no correlation between valve size and
regression of LV hypertrophy.19 In the meta-analysis by Ku-
nadian and associates,20 the decrease in LV mass was sim-
ilar among different valve types. In another study,
Christakis and associates19 reported a similar regression
of LV hypertrophy with 3 different valve sizes. In this study,
a statistically significant decrease in LV mass and LVMI
were observed with the 2 valve types and all valve sizes.
The primary objective of this study was to compare TTE
with cardiac MRI in the assessment of decrease in LV mass
and LVMI. Current clinical practices rely mostly on TTE
for measurements of LV mass because it is readily available644 The Journal of Thoracic and Cardiovascular Surgand correlates with contrast left ventriculography.11 How-
ever, although 2-dimensional echocardiography reliably
measures LV wall thickness and LV diameter at the base
of the heart, its calculation of the LV mass depends on the
Devereux formula, which has limitations in diseased states
because of the geometric assumptions it makes.9 Moreover,
TTE is acoustic window–dependent and subject to consid-
erable interobserver and intraobserver variability.13 In con-
trast, cardiac MRI yields precise and highly reproducible
measurements. Several studies have confirmed the accuracy
of cardiac MRI in the assessment of the hypertrophied left
ventricle.10,21-23 Bottini and colleagues21 found MRI to
more precisely and reliably measure LV mass than TTE
and to be more suitable to evaluate hypertensive patients.
Allison and coworkers22 made similar observations in pa-
tients with hypertrophic cardiomyopathy, although in our
study its seems that TTE grossly overestimated LV mass
and LVMI, as observed in other studies.24
Another advantage of cardiac MRI is the volumetric
quantification in the assessment of LV ejection fraction.
TTE, which is based on geometric assumptions, detected
a significant difference in LV ejection fraction between
baseline and 6 months limited to the Epic Supra group.
MRI recorded decreases in LV end-diastolic and end-
systolic volume, thus no change in stroke volume, and
statistically significant increases in LV ejection fraction
between baseline and 6 months with both valve models,
confirming its superiority versus echocardiography in the
measurements of volumes. The decrease in follow-up car-
diac output may be attributed to the slower heart rate, ex-
plained by the consumption of beta-adrenergic blockers in
50.3% of patients at 6 months versus 29.5% preoperatively.
Because of an approximately 10-fold higher cost of MRI
compared with TTE, its routine use for estimating LV massery c September 2012
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precision in its estimation is rarely needed. Despite this
fact, MRI is a good alternative in patients in whom TTE
is not possible or its quality is insufficient.
In conclusion, AVR using the Epic and Epic Supra bio-
prostheses results in a statistically significant decrease in
mean LVMI at 6 months after the operation. On the basis
of the results of this study and a review of the literature, it
seems that MRI is more accurate in measuring the dimen-
sions of the LV. An ultimate validation of this thesis could
only be done comparing each of these modalities with path-
ologic examination.
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TABLE E1. Incidence of clinical outcomes in 149 recipients of aortic Epic and Epic Supra bioprostheses at 30 days and 6 months of follow-up
Clinical events Epic (n ¼ 77) Epic Supra (n ¼ 72) All patients (n ¼ 149)
0-30 days
Death 2 (2.6) 1 (1.4) 3 (2.0)
Intrathoracic hemorrhage requiring reoperation 2 (2.6) 2 (2.8) 4 (2.7)
Atrial fibrillation 10 (13) 2 (2.8) 12 (8.1)
Complete heart block requiring permanent pacing 5 (6.5) 3 (4.2) 8 (5.4)
Pericardial effusion 3 (3.9) 0 (0) 3 (2.0)
Bleeding ulcer 0 (0) 1 (1.4) 1 (0.7)
1-6 months
Death 1 (1.3) 1 (1.4) 2 (1.4)
Valve thrombosis 0 (0) 1 (1.4) 1 (0.7)
Embolic stroke 0 (0) 1 (1.4) 1 (0.7)
Withdrawal from the study 6 (7.8) 1 (1.4) 7 (4.7)
Miscellaneous causes of missing data 8 (10.4) 6 (8.3) 14 (9.4)
Available data at 6 months 60 (77.9) 61 (84.7) 121 (81.2)
Values are numbers (%) of observations.
TABLE E2. Comparison of patients who did versus did not undergo
concomitant CABG surgery
Measurement
Patient group
CABG
(n ¼ 26)
No CABG
(n ¼ 123)
Age, y 73.3 73.3
Body mass index, kg/m2 28.4 27.8
Body surface area, m2 1.81 1.82
LV echocardiographic
Ejection fraction at baseline,% 68.9 68.4
Mass, g
At baseline 240 253
At follow-up 178 180
Δ LVMI, g/m2
On echocardiogram 35.8 38.8
On MRI 22.4 22.0
Values are means. Between-groups differences are all statistically nonsignificant.
CABG, Coronary artery bypass graft; LV, left ventricular; LVMI, left ventricular
mass index; MRI, magnetic resonance imaging.
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